Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment‐resistant depression
Giovanni Martinotti, Bernardo Dell’Osso, Giorgio Di Lorenzo, et al.
Bipolar Disorders (2023) Vol. 25, Iss. 3, pp. 233-244
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Diagnosis and management of bipolar disorders
Fernando S. Goes
BMJ (2023), pp. e073591-e073591
Open Access | Times Cited: 62
Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
Giacomo d’Andrea, Mauro Pettorruso, Giorgio Di Lorenzo, et al.
European Neuropsychopharmacology (2023) Vol. 70, pp. 49-55
Closed Access | Times Cited: 37
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study
Stefania Chiappini, Giacomo d’Andrea, Sergio De Filippis, et al.
European Neuropsychopharmacology (2023) Vol. 74, pp. 15-21
Open Access | Times Cited: 29
The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data
Giacomo d’Andrea, Mauro Pettorruso, Giorgio Di Lorenzo, et al.
Journal of Affective Disorders (2023) Vol. 348, pp. 314-322
Closed Access | Times Cited: 23
Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group
Giacomo d’Andrea, Stefania Chiappini, Roger S. McIntyre, et al.
American Journal of Geriatric Psychiatry (2023) Vol. 31, Iss. 12, pp. 1032-1041
Open Access | Times Cited: 22
Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)
Mauro Pettorruso, Roberto Guidotti, Giacomo d’Andrea, et al.
Psychiatry Research (2023) Vol. 327, pp. 115378-115378
Open Access | Times Cited: 22
Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis
Alessandro Rodolico, Pierfelice Cutrufelli, Antonio Di Francesco, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 8
Cariprazine Augmentation in Treatment-Resistant Bipolar Depression: Data from a Retrospective Observational Study
Elena Teobaldi, Enrico Pessina, Azzurra Martini, et al.
Current Neuropharmacology (2024) Vol. 22, Iss. 10, pp. 1742-1748
Open Access | Times Cited: 7
Anhedonia in bipolar depression treated with ketamine
Alina Wilkowska, Mariusz S. Wiglusz, Aleksandra Arciszewska, et al.
Bipolar Disorders (2024) Vol. 26, Iss. 4, pp. 356-363
Closed Access | Times Cited: 6
Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review
Matteo Di Vincenzo, Vassilis Martiadis, Bianca Della Rocca, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 5
How different definition criteria may predict clinical outcome in treatment resistant depression: Results from a prospective real-world study
Raffaella Zanardi, Matteo Carminati, Francesco Attanasio, et al.
Psychiatry Research (2024) Vol. 334, pp. 115818-115818
Closed Access | Times Cited: 4
Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression
Maxwell Zachary Price, Richard L. Price
Biomarkers in Neuropsychiatry (2024) Vol. 11, pp. 100104-100104
Open Access | Times Cited: 4
Ketamine and Esketamine for Depression in Daily Practice
Balwinder Singh
Journal of Clinical Psychopharmacology (2024) Vol. 44, Iss. 5, pp. 451-455
Closed Access | Times Cited: 4
Demographic and clinical predictors of response and remission in the treatment of major depressive disorder with ketamine and esketamine: A systematic review
Juliana Lima Constantino, Michael Godschalk, Jens H. van Dalfsen, et al.
Psychiatry Research (2025) Vol. 345, pp. 116355-116355
Open Access
Comment on “Efficacy of racemic ketamine or esketamine monotherapy for reducing suicidal ideation in uni- or bipolar depression: a systematic review and meta-analysis”
Alina Wilkowska, Wiesław Jerzy Cubała
European Archives of Psychiatry and Clinical Neuroscience (2025)
Closed Access
Effect of intravenous esketamine on postoperative sleep disturbance, anxiety, and depression in elderly patients undergoing laparoscopic abdominal surgery: a randomized controlled trial
Haijin Wang, Lan Wang, Jing Gao, et al.
BMC Geriatrics (2025) Vol. 25, Iss. 1
Open Access
Current evidence for the role of rapid-acting antidepressants (RAAD) in bipolar depression? A perspective and plan for action
Jonathan Repple, Maximilian Bayas, Christine Möser, et al.
Biological Psychiatry (2025)
Open Access
Global Trends in the Use of Pharmacotherapy for the Treatment of Bipolar Disorder
Anastasia K. Yocum, Balwinder Singh
Current Psychiatry Reports (2025)
Closed Access
Esketamine Nasal Spray Compassionate Use Program in the Netherlands: an open Label, Multi-Center Cohort Study in Severe Treatment-Resistant Depression
Abel Busz, Emma Schmidt, Rob van den Brink, et al.
Journal of Affective Disorders Reports (2025), pp. 100905-100905
Open Access
The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
Maria Pepe, Giovanni Bartolucci, Ilaria Marcelli, et al.
Brain Sciences (2023) Vol. 13, Iss. 10, pp. 1494-1494
Open Access | Times Cited: 10
Intravenous (IV) ketamine versus intranasal esketamine for depression– Advantage IV ketamine?
Balwinder Singh, Simon Kung, Jennifer L. Vande Voort
Journal of Affective Disorders (2024) Vol. 356, pp. 564-567
Closed Access | Times Cited: 3
Early effects predict trajectories of response to esketamine in treatment-resistant depression
Isaure Estrade, Anne‐Cécile Petit, Vincent Sylvestre, et al.
Journal of Affective Disorders (2023) Vol. 342, pp. 166-176
Open Access | Times Cited: 8
Short-term ketamine use in bipolar depression: a review of the evidence for short-term treatment management
Alina Wilkowska, Wiesław Jerzy Cubała
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 7
The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis
S. Danielle, Nicholas Kleine, Kayla M. Teopiz, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 1, pp. 5-14
Closed Access | Times Cited: 2
Pharmacological management of gambling disorder: an update of the literature
Gemma Mestre‐Bach, Marc N. Potenza
Expert Review of Neurotherapeutics (2024) Vol. 24, Iss. 4, pp. 391-407
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top